Company intelligence / Profile preview

Sensifree

Kfar Saba / Petach-Tikva, Central District, Israelprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

Sensifree has developed and commercialized the SentiCor 100, the world’s first PPG-based continuous non-invasive blood pressure monitor approved for hospital use under the new EU MDR. The device enables cuff-free, continuous BP monitoring to improve patient safety and outcomes in critical care. The company is also developing OEM solutions for integration into other medical devices[2].

Therapeutic areas: CardiovascularOther
Modalities: DeviceNon-pharmacological therapy (continuous non-invasive blood pressure monitoring)Biometric sensor technology (radio frequency-based, PPG-based)
Industry: Physiological Monitoring

Partnerships

Dreamtech Co., LTD (joint development of non-invasive BP/vital sign monitors)[4]

Beyond the preview

Go deeper on Sensifree.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sensifree.

Explore the full profile